Childhood pulmonary arterial hypertension: Insights from REVEAL

R. Barst, D. Ivy, C. G. Elliott, P. Wason, A. Foreman, D. Miller, M. McGoon (New York, Aurora, Murray, South San Francisco, San Francisco, Rochester, United States Of America)

Source: Annual Congress 2011 - Clinical features of pulmonary hypertension
Session: Clinical features of pulmonary hypertension
Session type: Thematic Poster Session
Number: 2327
Disease area: Pulmonary vascular diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Barst, D. Ivy, C. G. Elliott, P. Wason, A. Foreman, D. Miller, M. McGoon (New York, Aurora, Murray, South San Francisco, San Francisco, Rochester, United States Of America). Childhood pulmonary arterial hypertension: Insights from REVEAL. Eur Respir J 2011; 38: Suppl. 55, 2327

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Risk assessment in pulmonary arterial hypertension (PAH): Insights from the GRIPHON study
Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension
Year: 2018




REVEAL: a contemporary US pulmonary arterial hypertension registry
Source: Eur Respir Rev 2012; 21: 8-18
Year: 2012


Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014


Molecular study of genetic modifiers in patients with pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs
Year: 2014

Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014


Quality of life of patients with pulmonary arterial hypertension associated with congenital heart disease: The multicenter cross-sectional ACHILLE study
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014


Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1800279; 10.1183/13993003.00279-2018
Year: 2018



Risk assessment in pulmonary arterial hypertension
Source: Eur Respir Rev 2016; 25: 390-398
Year: 2016



Risk assessment in pulmonary arterial hypertension
Source: Eur Respir J, 51 (3) 1702606; 10.1183/13993003.02606-2017
Year: 2018



Exercise-induced pulmonary hypertension in patients with systemic sclerosis: Pilot-study
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014


Would RDW be a prognostic factor in pulmonary arterial hypertension?
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014

Long-term data from the Swiss pulmonary hypertension registry
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014

LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension
Source: International Congress 2014 – New technologies and biomarkers in lung disease
Year: 2014


Pulmonary arterial hypertension – A single-centre experience
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014


Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups
Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology
Year: 2014


Pulmonary arterial hypertension in Adult-Onset Still’s Disease
Source: Virtual Congress 2021 – All about pulmonary arterial hypertension
Year: 2021



HbA1c-levels in patients with operable chronic thromboembolic pulmonary hypertension
Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension
Year: 2014


Risk status at selexipag initiation in pulmonary arterial hypertension (PAH): Insights from EXPOSURE
Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension
Year: 2020


Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
Source: Eur Respir J 2015; 46: 1711-1720
Year: 2015



Correlations between clinical variables and quality of life in pulmonary arterial hypertension
Source: International Congress 2014 – Pulmonary hypertension: clinical management
Year: 2014